Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

In recent years, many patients like Mitchell have faced soaring insulin costs. These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and ...

The lawsuits generally make two claims: that insulin prices are unreasonably high and that drug companies and PBMs are responsible. The lawsuits are on firmer ground in their claim that PBMs are ...

INSULIN LITIGATION DEEP-DIVE — As Congress weighs legislation to rein in pharmacy benefit managers, a lawsuit accusing PBMs and insulin makers of racketeering and unfair trade practices is ...

The companies, known as PBMs, are accused of excluding available insulin products with lower prices — which could have been more affordable for patients — in favor of higher-priced insulins ...

Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason for the sharp ...

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

PBMs negotiate drug prices and rebates with manufacturers for their employer and health plan customers. A Novo Nordisk ...

It claims that the PBMs have been rigging pharma supply chain competition in their favour in pursuit of profit, impairing patients' access to lower list price insulin products, and shifting the ...

Even when lower list-price insulins became available, the PBMs excluded those options for patients and provided higher prices and highly rebated insulin products, the agency alleges. "Millions of ...

The suit follows legal action over insulin pricing taken by other states, including Arkansas, Kansas, Mississippi, and Minnesota. "We're fighting back against drug companies and PBMs that ...

The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and ...